Nrf2, the Master Regulator of Anti-Oxidative Responses.
Vomund S, Schäfer A, Parnham MJ, Brüne B, von Knethen A. · 2017
Read Nrf2, the Master Regulator of Anti-Oxidative Responses. by Vomund S, Schäfer A, Parnham MJ, Brüne B, von Knethen A. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5751370.txt.
Introduction
Vomund and co-authors review Nrf2, a master switch for antioxidant defense. When oxidative stress frees it, Nrf2 turns on protective genes. That response helps end inflammation and start healing. Too much or too little Nrf2 activity can feed chronic disease.
The review sets out how Nrf2 is kept in check in calm times. Keap1 targets it for breakdown until stress signals intervene. Links with inflammation paths and with autophagy get close attention. Faulty Nrf2 control also plays a part in tumor growth. The authors weigh drug ideas that aim to restore its balance.
Catalog record
| CREATOR | Vomund S, Schäfer A, Parnham MJ, Brüne B, von Knethen A. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Nrf2, the Master Regulator of Anti-Oxidative Responses By Sandra Vomund, Anne Schäfer, Michael J Parnham, Bernhard Brüne, Andreas von Knethen Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms18122772 ABSTRACT Abstract Tight regulation of inflammation is very important to guarantee a balanced immune response without developing chronic inflammation. One of the major mediators of the resolution of inflammation is the transcription factor: the nuclear factor erythroid 2-like 2 (Nrf2). Stabilized following oxidative stress, Nrf2 induces the expression of antioxidants as well as cytoprotective genes, which provoke an anti-inflammatory expression profile, and is crucial for the initiation of healing. In view of this fundamental modulatory role, it is clear that both hyper- or hypoactivation of Nrf2 contribute to the onset of chronic diseases. Understanding the tight regulation of Nrf2 expression/activation and its interaction with signaling pathways, known to affect inflammatory processes, will facilitate development of therapeutic approaches to prevent Nrf2 dysregulation and ameliorate chronic inflammatory diseases. We discuss in this review the principle mechanisms of Nrf2 regulation with a focus on inflammation and autophagy, extending the role of dysregulated Nrf2 to chronic diseases and tumor development. Keywords: Nrf2, electrophiles, reactive oxygen species, transcription factor, antioxidants 1. STRUCTURE AND REGULATION OF NRF2 The CNC (cap-n-collar) subfamily of the basic region-leucine zipper-type transcription factor Nrf2 is encoded by the nuclear factor, erythroid-derived 2-like 2 (NFE2L2) gene [1]. As shown in Figure 1A, Nrf2 contains six Neh (Nrf2-ECH homology) domains. The Neh1 domain includes a basic region-leucine zipper (bZIP) structure, which is important for Nrf2 dimerization with small Maf proteins (sMafs) [2] and binding to DNA. Neh2 and Neh6 are degrons, which allow Nrf2 targeting to proteasomal degradation by Keap1 (Kelch-like ECH-associated protein1) and β-TrCP (β-transducin repeats-containing proteins) [3]. The Neh4 and Neh5 domains are responsible for Nrf2-dependent transactivation. [Figure: Regulation of Nrf2 expression. (A) Domain structure of Nrf2; (B) Keap1-dependent degradation of Nrf2 (mod. from [8]), T-bar = inhibition of Nrf2 degradation, consequently blocking Keap1 release; (C) Keap1-independent mechanism of Nrf2 degradation.] As a master regulator of antioxidative responses, the expression of Nrf2 is tightly regulated. Under healthy conditions, Nrf2 mRNA is constitutively expressed [4] and Nrf2 expression is controlled at the protein level [5]. Following translation, Nrf2 is targeted by a Keap1 homodimer in the cytosol, which facilitates binding of the Cullin-3 (Cul3)/RING box protein1 (Rbx1) E3 ubiquitin ligase complex, consequently causing proteasomal degradation of Nrf2 [6] (Figure 1B). Binding of the Keap1 homodimer is mediated by the two Nrf2 sequences, ETGE and DLGex, located in the Neh2 domain [7]. In single live cells, it has been shown that in the control situation, the interaction of Nrf2 and Keap1 follows a cycle, whereby Nrf2 interacts with a single molecule of Keap1 (open confirmation, Figure 1B, basal state), followed by a closed conformation, in which Nrf2 binds to both members of the Keap1 dimer [8,9]. This closed conformation is stabilized by inducers (Figure 1B, induced state), without releasing Nrf2. Consequently, free Keap1 is not regenerated. Thus, de-novo synthesized Nrf2 is stabilized, translocates to the nucleus and induces expression of cytoprotective target genes [10]. These are mainly responsible for detoxification, antioxidation, and metabolism [11]. Moreover, Nrf2 inhibits activation of pro-inflammatory gene expression [12]. To fulfill its role as a transcription factor, Nrf2 binds, as a heterodimer with one of the sMafs, to the antioxidant-response-element (ARE) or electrophile-response element (EpRE) [13,14]. This is located in the promoter/enhancer regions of many cytoprotective genes. After gene induction, Nrf2 is phosphorylated within the nucleus by the SRC family tyrosine kinase member, Fyn (Figure 1C). Fyn translocates to the nucleus in response to its threonine phosphorylation by active glycogen synthase kinase 3β (GSK-3β) [15]. There, activated Fyn phosphorylates Nrf2 at Tyr568, which leads to nuclear export and cytosolic degradation of Nrf2 [16]. Alternatively, in the cytosol, GSK-3β can also directly phosphorylate Ser335 and Ser338 of Nrf2, located in the Neh6 domain. This phosphorylated Nrf2 translocates to the nucleus and is recognized directly by β-transducin repeat containing E3 ubiquitin protein ligase (β-TrCP) (Figure 1C), provoking nuclear ubiquitination and degradation of Nrf2 [17]. Additionally to Nrf2 degradation as a mechanism to prevent Nrf2-dependent target gene induction, the BTB and CNC homology 1 (Bach1) transcription factor competes with Nrf2 for its binding sites on DNA, consequently suppressing Nrf2-mediated gene induction [18]. 2. NRF2 AND AUTOPHAGY The Nrf2-Keap1 signaling pathway and its subsequent induction of cytoprotective protein expression is the main cellular defense mechanism against oxidative and electrophilic stress. Therefore, interactions of Nrf2 with other signaling components regulate the efficiency of the cellular stress response. One of these is macroautophagy (hereafter referred to as autophagy). In general, autophagy preserves cellular homeostasis and protects against oxidative and proteotoxic stress by clearance of damaged organelles, long-lived proteins, as well as misfolded and aggregated proteins. This intracellular bulk degradation is executed through engulfment by double-membrane vesicles, named autophagosomes, which fuse with lysosomes [19]. Autophagy can be non-selective, especially induced by starvation, but there is also a basal autophagy that selectively sorts proteins and unwanted organelles to maintain cellular homeostasis [20]. Nrf2 activation interferes with selective autophagy. In this case, the Nrf2 inhibitor Keap1 affects p62/sequestosome 1 (SQSTM1)-dependent signaling [21]. The p62/SQSTM1 protein is a ubiquitously expressed cellular protein, also known as A170, found in inclusion bodies containing polyubiquitinated protein aggregates. Through binding to microtubule-associated protein 1 light chain 3 (LC3), a well characterized autophagy marker, p62/SQSTM1 leads these inclusion bodies into the autophagosome where the proteins are digested (Figure 2). Therefore, p62/SQSTM1 acts as an adaptor between polyubiquitinated proteins and autophagy. As shown in Figure 2A, the domain structure of p62/SQSTM1 facilitates the binding of various proteins, such as Raptor, extracellular regulated kinase 1 (Erk1), atypical protein kinase C (aPKC), TNF-receptor associated factor 6 (TRAF6), receptor-interacting serine/threonine-protein kinase 1 (RIP1), and Keap1. This multifunctionality points to an important role of p62/SQSTM1 in intracellular signaling [22]. Inclusion bodies have been found to accumulate in several human diseases, especially in neurodegenerative diseases (Huntington disease, Parkinson disease, Alzheimer disease, and amyotrophic lateral sclerosis), but also in liver disorders, such as alcoholic hepatitis, steatohepatitis, and cancer [23,24,25]. Komatsu and co-workers have shown that suppression of autophagy leads to the formation of ubiquitin-positive inclusion bodies in mouse models [26,27]. This group also found that NAD(P)H quinone dehydrogenase 1 (Nqo1) and glutathione S-transferase (Gst), as Nrf2-regulated proteins, accumulate together with p62/SQSTM1 in autophagy-deficient mice and that Keap1 directly interacts with p62/SQSTM1, to be degraded within the autophagosome. Binding of p62/SQSTM1 to Keap1 occurs at the Kelch domain of Keap1, which is also one of the binding sites for Nrf2. Therefore, accumulation of p62/SQSTM1, for example due to autophagy deficiency, sequesters Keap1 and results in the release and stabilization of Nrf2 [28]. Nrf2 then translocates into the nucleus and activates expression of its target genes. One of these is p62/SQSTM1 itself, pointing to a positive feedback loop in the activation of Nrf2 and initiation of selective autophagy via p62/SQSTM1 [29]. This feedback loop is problematic for cancer therapy. Chemotherapy induced autophagy is thought to protect cancer cells from apoptosis. Nrf2 activation promotes the resistance of cancer cells to stress induced by chemotherapeutic drugs [30,31]. Thus, autophagy deficiency and consequent accumulation of p62/SQSTM1 is suspected to be tumorigenic [32]. [Figure: Positive feedback-loop of Nrf2